Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Oxford Nanopore Technologies Raises £109.5M

Oxford Nanopore Technologies Raises £109.5M

Jan 02, 2020
|
staff reporter

NEW YORK – Oxford Nanopore Technologies said Thursday it has raised a total of £109.5 million ($144.4 million) between new capital investments and the sale of secondary shares.

The privately held, UK-based firm said it raised £29.3 million in capital and sold £80.2 million in shares. The investors include both new and existing shareholders from the US, Europe, and Asia/Pacific regions, the firm said in a statement.

Other details, including how the firm plans to use the proceeds, were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Sequencing

  1. FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

  2. At AGBT, Two Labs Share SARS-CoV-2 Genomic Surveillance Experience

    Premium

  3. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  4. Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

  5. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.